Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404505 | 0.89 | CHRM2 (0.53) | KMT2AMEN1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4412232 | 0.88 | KDM4E (0.51) | KMT2AMEN1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4414892 | 0.88 | SMARCA2 (0.56) | KMT2AMEN1L3MBTL1ALDH1A1HTT | |
| SCHEMBL4406672 | 0.86 | ALDH1A1 (0.52) | KMT2AMEN1L3MBTL1ATMALDH1A1 | |
| SCHEMBL4409089 | 0.85 | CHRM2 (0.57) | KMT2AMEN1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL18768851 | 0.85 | KMT2A (0.68) | KMT2AMEN1L3MBTL1ATMALDH1A1 | |
| SCHEMBL4413896 | 0.84 | KDM4E (0.46) | KMT2AMEN1L3MBTL1ALDH1A1HTT | |
| SCHEMBL4404508 | 0.84 | KMT2A (0.43) | KMT2AMEN1L3MBTL1ALDH1A1HTT | |
| SCHEMBL4404341 | 0.83 | KDM4E (0.50) | KMT2AMEN1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL4413514 | 0.83 | KDM4E (0.50) | KMT2AMEN1L3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608352-B1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2009-12-30 | — | — | EP | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| WO-2008021788-A2 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (CN) | 2008-02-21 | — | — | WO | disclosed |
| EP-1608352-A4 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2007-11-28 | — | — | EP | disclosed |
| EP-1608352-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | Taigen Biotechnology (TW) | 2005-12-28 | — | — | EP | disclosed |
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2005-02-24 | — | — | US | disclosed |
| WO-2004089360-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | CCL2, CCR2, CCR5 | KMT2A 2409/4885MEN1 2115/4885L3MBTL1 2576/4885 |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | SRM, SMS, SMOX | KMT2A 1163/4885MEN1 762/4885L3MBTL1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.